Dr. Kornelis Poelstra, a Las Vegas-based spine surgeon, has completed his 2,000th robotic-assisted spine procedure after 16 years of experience across multiple robotic platforms including SpineAssist, Renaissance, Mazor X, LEM, and Mako. The milestone reflects growing clinical experience in robotic-guided spine surgery, with published studies suggesting these systems may improve implant placement accuracy compared to conventional techniques.

The global computer vision in healthcare market is projected to grow from $4.37 billion in 2026 to $33.4 billion by 2036, at a CAGR of 22.6%. Growth is driven by AI-integrated diagnostic systems, radiologist shortages, and precision medicine adoption. Software and medical imaging segments lead the market, while Asia-Pacific is expected to see the fastest regional growth.

Stryker has completed its acquisition of Amplitude Vascular Systems, a Boston-based medical device company specializing in intravascular lithotripsy (IVL) technology for treating complex peripheral arterial disease. The acquisition strengthens Stryker's peripheral vascular portfolio by integrating AVS's innovative CO₂-generated pressure wave technology with Stryker's resources and scale.

Stryker Corporation announced a quarterly dividend increase of 4.8% to $0.88 per share, payable July 31, 2026. The company reported first quarter 2026 operating results with net sales increasing 2.6% to $6.0 billion, demonstrating continued growth in its medical technology business across MedSurg, Neurotechnology, and Orthopaedics segments.

Becton Dickinson (BDX) trades at a 13x forward P/E multiple, representing a significant discount to medtech peers despite strong fundamentals including 60% U.S. infusion pump market share, 90%+ recurring revenue, and record 25% adjusted operating margins. The post-spin-off transition year narrative masks an emerging pure-play MedTech company with billion-dollar growth platforms in GLP-1 drug delivery and connected care, supported by $4 billion in fresh capital deployment and ongoing margin expansion targeting 26%+ territory.

The global laparoscopy devices market is projected to grow from USD 11.1 billion in 2025 to USD 23.5 billion by 2034, driven by rising incidence of gastrointestinal and urological conditions, growing preference for minimally invasive surgeries, technological innovations, and expanding healthcare infrastructure. North America leads with 41% market share, while Asia-Pacific emerges as a significant growth engine.

The global surgical drill bits market was valued at USD 316 million in 2025 and is projected to reach USD 540 million by 2035, growing at a CAGR of 5.5%. Growth is driven by healthcare infrastructure development in emerging economies, increased surgical procedures, and rising demand for infection prevention measures. Hospitals are expected to dominate the market segment, while North America leads in market share and Asia-Pacific shows the highest growth rate.

The global foot and ankle devices market is projected to grow from USD 5.9 billion in 2025 to USD 9.2 billion by 2034, driven by rising incidence of foot and ankle conditions, diabetes-related complications, aging populations, and technological advancements in minimally invasive procedures and 3D-printed implants. North America leads the market, with key players including DePuy Synthes, Stryker, and Zimmer Biomet driving innovation through recent product launches and strategic developments.

The global ambulatory surgical equipment market is valued at USD 7.39 billion in 2026 and is expected to reach USD 14.58 billion by 2035, growing at a 7.85% CAGR. North America dominates with 34% market share, while Asia Pacific is the fastest-growing region. Endoscopy and laparoscopy systems lead by product type at 18% share, with compact intraoperative imaging expected to grow fastest. Independent ambulatory surgical centers account for 42% of the market.

Stryker announced it will release its first quarter fiscal year 2026 financial results on April 30, 2026, with a press release at 4:05 p.m. ET followed by a webcast at 4:30 p.m. ET to discuss the results for the quarter ended March 31, 2026.

Boston Scientific shares fell 9.02% on March 30, 2026, after the company announced results from its CHAMPION-AF clinical trial for the Watchman FLX heart implant. While the trial met all safety and efficacy endpoints, analysts considered the results underwhelming and expressed concerns that growth may not accelerate as expected. Despite the decline, analysts maintained outperform ratings, noting the stock is reasonably valued at 18x forward earnings.

Stryker announced its 2026 Annual Meeting of Shareholders scheduled for May 6, 2026, to be held virtually. The company also declared a quarterly dividend of $0.88 per share payable on April 30, 2026. Stryker is a global leader in medical technologies serving over 150 million patients annually across MedSurg, Neurotechnology, and Orthopaedics segments.